Associations Among Hypogonadism, C-Reactive Protein, Symptom Burden, and Survival in Male Cancer Patients with Cachexia: A Preliminary Report

Journal of Pain and Symptom Management

Volumn 39, Issue 6, 2010, Pages 1016-1024

  Del Fabbro, Egidio ^a   Hui, David ^a   Nooruddin, Zohra I ^a   Dalal, Shalini ^a   Dev, Rony ^a   Freer, Gina ^a   Roberts, Lynn ^a   Palmer, J Lynn ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cachexia; hypogonadism; inflammatory marker; survival; symptoms

Indexed keywords

C REACTIVE PROTEIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CACHEXIA; CANCER PATIENT; CANCER SURVIVAL; DISEASE ASSOCIATION; DYSPNEA; HUMAN; HYPOGONADISM; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CACHEXIA; COST OF ILLNESS; HUMANS; HYPOGONADISM; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL; SURVIVAL ANALYSIS; TESTOSTERONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953122018     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2009.09.021     Document Type: Article

References (40)

1. Shores M.M., Matsumoto A.M., Sloan K.L., and Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
2. Seidman S.N., and Roose S.P. The sexual effects of testosterone replacement in depressed men: randomized, placebo-controlled clinical trial. J Sex Marital Ther 32 (2006) 267-273
3. Chlebowski R.T., and Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 42 (1982) 2495-2498
4. Greenfield D.M., Walters S.J., Coleman R.E., et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab 92 (2007) 3476-3482
5. Huddart R.A., Norman A., Moynihan C., et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 93 (2005) 200-207
6. Dev R., Del Fabbro E., and Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 110 (2007) 1173-1177
7. Gerl A., Muhlbayer D., Hansmann G., Mraz W., and Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91 (2001) 1297-1303
8. Strasser F., Palmer J.L., Schover L.R., et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107 (2006) 2949-2957
9. Rajagopal A., Vassilopoulou-Sellin R., Palmer J.L., Kaur G., and Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100 (2004) 851-858
10. Hashimoto K., Ikeda Y., Korenaga D., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103 (2005) 1856-1864
11. Hefler L.A., Concin N., Hofstetter G., et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14 (2008) 710-714
12. Garcia J.M., Li H., Mann D., et al. Hypogonadism in male patients with cancer. Cancer 106 (2006) 2583-2591
13. Traish A.M., Saad F., and Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30 (2009) 23-32
14. Yialamas M.A., Dwyer A.A., Hanley E., et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92 (2007) 4254-4259
15. Chang V.T., Hwang S.S., and Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 88 (2000) 2164-2171
16. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91 (2006) 1995-2010
17. Roscoe J.A., Kaufman M.E., Matteson-Rusby S.E., et al. Cancer-related fatigue and sleep disorders. Oncologist 12 Suppl 1 (2007) 35-42
18. Lis C.G., Gupta D., and Grutsch J.F. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer 16 (2008) 261-266
19. Luboshitzky R., Wagner O., Lavi S., Herer P., and Lavie P. Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment. Clin Endocrinol (Oxf) 47 (1997) 463-469
20. Karadag F., Ozcan H., Karun A.B., Gilman M., and Clad O. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int J Clin Pract 63 (2009) 275-281
21. McKeown D.J., Brown D.J., Kelly A., Wallace A.M., and McMillan D.C. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 91 (2004) 1993-1995
22. Vgontzas A.N., Bixler E.O., Lin H.M., et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12 (2005) 131-140
23. Rich T., Innominato P.F., Boerner J., et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005) 1757-1764
24. Allin K.H., Bojesen S.E., and Nordestgaard B.G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27 (2009) 2217-2224
25. Groblewska M., Mroczko B., Wereszczyńska-Siemiatkowska U., et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46 (2008) 1423-1428
26. Ramsey S., Lamb G.W., Aitchison M., Graham J., and McMillan D.C. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109 (2007) 205-212
27. Al Murri A.M., Bartlett J.M., Canney P.A., et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94 (2006) 227-230
28. Crumley A.B., McMillan D.C., McKernan M., McDonald A.C., and Stuart R.C. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 94 (2006) 637-641
29. Pfitzenmaier J., Vessella R., Higano C.S., et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 (2003) 1211-1216
30. Martin F., Santolaria F., Batista N., et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11 (1999) 80-86
31. Maltoni M., Fabbri L., Nanni O., et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 5 (1997) 130-135
32. Jatoi A., Egner J., Loprinzi C.L., et al. Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. Support Care Cancer 12 (2004) 640-644
33. Isbarn H., Boccon-Gibod L., Carroll P.R., et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 55 (2009) 62-75
34. Taira A.V., Merrick G.S., Galbreath R.W., et al. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 74 (2009) 1143-1149
35. Carrero J.J., Qureshi A.R., Parini P., et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 20 (2009) 613-620
36. Corrales J.J., Almeida M., Burgo R., et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189 (2006) 595-604
37. Malkin C.J., Pugh P.J., Jones R.D., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004) 3313-3318
38. Kapoor D., Clarke S., Stanworth R., Channer K.S., and Jones T.H. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156 (2007) 595-602
39. Marks L.S., Mazer N.A., Mostaghel E., et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296 (2006) 2351-2361
40. Fowler Jr. J.E., and Whitmore Jr. W.F. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126 (1981) 372-375